"The underlying business is not broken. Q4 2025 adjusted EPS came in at $0.59 against an estimate of $0.34, a 73.58% beat, while revenue of $846.79 million edged past the $839.55 million consensus. Customer retention held above 95% for the 12th consecutive year. What spooked investors was the deceleration: Q1 2026 guidance calls for revenue of at least $678 million, implying roughly 10% growth, which is a step down from the 18% pace delivered in full-year 2025."
"Moderna has surged 82.54% year-to-date to $53.83, and the bounce has run well past what Wall Street endorses. The consensus price target is $42.90, or roughly 20% below where the stock trades today. Of 24 analysts covering Moderna, 18 rate it Hold, two Sell, and two Strong Sell, with just three carrying any bullish rating. That is one of the most skeptical"
Trade Desk rebounded 24.38% recently but remains 55% below year-ago levels, with analyst consensus showing mixed conviction and a price target just 7% above current levels. The company beat Q4 earnings estimates significantly and maintained 95%+ customer retention, but Q1 guidance suggests deceleration to 10% growth from 18% full-year 2025 pace. Moderna surged 82.54% year-to-date to $53.83, trading 20% above the $42.90 consensus price target, with 18 of 24 analysts rating it Hold and only three bullish. Strategy demonstrates stronger analyst support despite being among 2026's most volatile names, with conviction levels diverging sharply across all three stocks.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]